pirfenidone has been researched along with Heart Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M | 1 |
| Avila, G; Osornio-Garduño, DS; Ramos-Mondragón, R; Ríos-Pérez, EB | 1 |
| Al-Bayati, MA; Du, X; Giri, SN; Margolin, SB; Mohr, FC; Schelegle, E | 1 |
2 review(s) available for pirfenidone and Heart Diseases
| Article | Year |
|---|---|
Pirfenidone. First, do no harm.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Heart Diseases; Humans; Pulmonary Fibrosis; Pyridones; Risk Assessment | 2013 |
Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus.
Topics: Calcium; Calcium Channels; Diabetes Mellitus; Heart Diseases; Humans; Myocardium; Myocytes, Cardiac; Pyridones; Transforming Growth Factor beta1 | 2014 |
2 other study(ies) available for pirfenidone and Heart Diseases
| Article | Year |
|---|---|
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation | 2021 |
Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Body Weight; Diet; Doxorubicin; Eating; Heart Diseases; Hemodynamics; Kidney; Kidney Diseases; Male; Myocardium; Pyridones; Rats; Rats, Sprague-Dawley; Respiratory Function Tests | 2004 |